Cytotoxicity Test of N'-E-benzylidene benzohydrazide in UM-UC-3 and MDA-MB-231 Cell Line

Nadia Azhaar 1, *, Fahimah Martak 2 and Awik Puji Dyah Nurhayati 1

1 Department of Biology, Faculty of Science and Data Analytics, Institute Technology Sepuluh Nopember, Surabaya, Indonesia.
2 Department of Chemistry, Faculty of Science and Data Analytics, Institute Technology Sepuluh Nopember, Surabaya, Indonesia.
 
Research Article
International Journal of Science and Research Archive, 2024, 11(01), 786–790.
Article DOI: 10.30574/ijsra.2024.11.1.0094
Publication history: 
Received on 08 December 2023; revised on 20 January 2024; accepted on 23 January 2024
 
Abstract: 
The current anticancer therapy strategy that can be done is chemotherapy. Although cisplatin has become a common drug for the clinical treatment of solid tumors, its use has been largely limited due to the inherent and acquired resistance and severe toxic side effects in normal tissues. The search for anticancer drugs continues to this day. Hydrazone compounds are a group of organic compounds derived from reactions between aldehydes or ketones and hydrazine. Hydrazone contains an azomethine bond -CH=N-NH- which has anticancer and antitumor activity. This study aims to determine the cytotoxicity of N'-E-benzylidene benzohydrazide compounds on UM-UC-3 and MDA-MB-231 cancer cell lines. Cytotoxicity analysis was carried out using CCK-8 to obtain the Inhibitory Concentration (IC50) value with a nonlinear regression test using GraphPad Prism 8.3.0 for Windows software. The compound N'-E-benzylidene benzohydrazide was shown to have a lower IC50 value in the MDA-MB-231 cell line at a concentration of 100 µM namely 482 µM. Therefore, the study concludes that N'-E-benzylidene benzohydrazide is still toxic to cancer cell lines, particularly UM-UC-3 and MDA-MB-231 cell lines. More research will be needed before this compound may be used as an anticancer medication in the future.
 
Keywords: 
Cancer; Cytotoxic; CCK-8; Hydrazone
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0